<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378713</url>
  </required_header>
  <id_info>
    <org_study_id>TESTOPRIM</org_study_id>
    <nct_id>NCT03378713</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Effect of Testosterone in Patients With Poor Ovarian Response (TESTOPRIM)</brief_title>
  <acronym>TESTOPRIM</acronym>
  <official_title>Clinical Effect of Follicular Preparation With Testosterone in Poor Ovarian Response: a Randomized Controlled Clinical Trial (TESTOPRIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to determine the absolute and relative efficacy of two follicular preparation regimens
      with transdermal testosterone during the cycle (s) prior to the initiation of COS (controlled
      ovarian stimulation) in patients diagnosed with POR (poor ovarian response) for the increase
      in the number of mature oocytes recovered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      POR is a challenge for reproductive medicine because of its impact on treatment outcomes and
      the lack of sufficiently proven therapeutic tools. According to recent publications based on
      retrospective studies of large registries, there is a correlation between the number of
      oocytes and LBR (live birth rate), so the investigators consider that variable mature oocytes
      are a reasonable compromise and a solid substitute for other outcome variables such as LBR or
      CPR (clinical pregnancy rate).

      Regarding the duration of treatment, the investigators decided to include two groups of
      testosterone treatment (compared to the control group) with different duration. One will
      explore the role of testosterone in prolonged treatments (two full menstrual cycles). The
      other will test the pattern most commonly used in most studies, that is, testosterone in
      luteal phase of the previous cycle (about 10 days in short protocol with GnRH antagonist). In
      this way the investigators will establish an absolute comparison with the control group and
      relative between both treatment groups (long testosterone vs. short testosterone) to
      determine if / which of the two regimen (the two, only one or none) improves the number of
      mature oocytes recovered.

      The product under investigation is testosterone gel, transdermal administration, 50 mg /
      single dose (TestimÂ®, Ferring, Madrid, Spain). Regarding the dose, the investigators decided
      to keep the most used in the rest of studies (12.5 mg / day).

      This study population will include only patients diagnosed with POR based on ESHRE Bologna
      criteria, in order to homogenize the population and allow comparisons with other studies in
      the future.

      Regarding the dose, the investigators decided to keep the most used in the rest of studies
      (12.5 mg/day) which so far has been the only one proven effective. It is clearly possible
      that lower and more physiological doses are equally effective, but this yet has to be proven
      in well-designed studies. The gel is self-administered by the patients who are adequately
      instructed by a research nurse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2017</start_date>
  <completion_date type="Anticipated">August 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of mature oocytes obtained at follicular puncture.</measure>
    <time_frame>36 hours after induction of ovulation with recombinant HCG.</time_frame>
    <description>Determining whether a Follicular preparation with transdermal testosterone increases the number of mature oocytes retrieved in patients diagnosed with Poor Ovarian Response and which testosterone administration regimen is more effective for this purpose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of obtained embryos</measure>
    <time_frame>6 days after ovarian puncture.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antral follicles at the start of stimulation</measure>
    <time_frame>Time E: prior to controlled ovarian stimulation (at the beginning of the third cycle after inclusion and randomization, approximately 56 days after Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation rate</measure>
    <time_frame>Time E: prior to controlled ovarian stimulation (at the beginning of the third cycle after inclusion and randomization, approximately 56 days after Day 0)</time_frame>
    <description>Quotient between the number of patients initiating COS and the total number of patients, overall and in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of stimulation duration</measure>
    <time_frame>Time P (time of follicular puncture): 36 hours after the induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of total follicles and greater than 16 mm</measure>
    <time_frame>Time I (Day of induction): 10-12 days after controlled ovarian stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of gonadotrophins used</measure>
    <time_frame>Time I (Day of induction): 10-12 days after controlled ovarian stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate due to lack of ovarian response</measure>
    <time_frame>Time C: 10-12 days after controlled ovarian stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cumulus-oocyte complexes recovered on day of follicular puncture</measure>
    <time_frame>Time P (time of follicular puncture): 36 hours after the induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>24 hours after the puncture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cycles that achieve embryo transfer</measure>
    <time_frame>Time ET ( day of embryo transfer): 4-5 days after the stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of good quality embryos available</measure>
    <time_frame>48-72 hours after puncture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos transferred</measure>
    <time_frame>Time ET (day of embryo transfer): 4-5 days after the stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cycles with supernumerary embryos to freeze</measure>
    <time_frame>6 days after embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate per cycle started and per transfer</measure>
    <time_frame>70-75 days after embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate per cycle started and per transfer</measure>
    <time_frame>30-35 days after embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>At 11-13 weeks of pregnancy, if there is no previous news of the patient (Trial completion time)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hormone levels</measure>
    <time_frame>Day 0; Time I (day of induction): 10-12 days after controlled ovarian stimulation; and Time E (prior to controlled ovarian stimulation: at the beginning of the third cycle after inclusion and randomization, approximately 56 days after Day 0)</time_frame>
    <description>Serum hormone levels of FSH, LH, E2, progesterone, testosterone, androstenedione, DHEA, SHBG and FAI</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>GROUP 1: Long testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 2: Short testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 3: Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The COS starts directly on the second day of the cycle without prior medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP 1: Long testosterone</intervention_name>
    <description>Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application</description>
    <arm_group_label>GROUP 1: Long testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP 2: Short testosterone</intervention_name>
    <description>Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.</description>
    <arm_group_label>GROUP 2: Short testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP 3: Control</intervention_name>
    <description>The COS starts directly on the second day of the cycle without prior medication.</description>
    <arm_group_label>GROUP 3: Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed consent prior to the completion of any procedure related to the
             clinical trial.

          -  Female older than 18 years old at the time of randomization.

          -  Prior diagnosis of poor ovarian response (POR) according to ESHRE Bologna criteria.
             Patients must meet at least 2 of the following:

               -  Advanced maternal age (40 years or more) or any other risk factor for POR.

               -  A previous POR (3 oocytes or less) with a conventional ovarian stimulation
                  protocol.

               -  Abnormal ovarian reserve test (RFA &lt;5-7 or AMH 3.3-7.9 pmol / l).

        Exclusion Criteria:

          -  Presence of uterine malformations, corrected or not.

          -  Presence of uterine pathology defined as submucous myomas or endometrial polyps,
             documented by transvaginal ultrasound.

          -  Couples with severe male factor defined as REM &lt;1 or azoospermia.

          -  Hydrosalpinx unilateral or bilateral uncorrected.

          -  Perimenopausal patients with irregular menstrual cycles.

          -  Concurrent untreated endocrine disorders.

          -  Patients who have participated in a clinical trial in a period of less than one month.

          -  Known allergy to the drug.

          -  Patients who have received androgen treatment within 3 months prior to inclusion in
             the study.

          -  BMI&gt; 35 kg / m2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>the trial treats female infertility</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica SubirÃ¡</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari i PolitÃ¨cnic La Fe, Valencia, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Cortell</last_name>
    <phone>0034961246611</phone>
    <email>investigacion_clinica@iislafe.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario y PolitÃ©cnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cortell</last_name>
      <phone>0034961246611</phone>
      <email>investigacion_clinica@iislafe.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update. 2003 Jan-Feb;9(1):61-76. Review.</citation>
    <PMID>12638782</PMID>
  </reference>
  <reference>
    <citation>Gorgy A, Naumann N, Bates S, Craft IL. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997 Dec;104(12):1420-1.</citation>
    <PMID>9422028</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <reference>
    <citation>Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril. 2009 Mar;91(3):749-66. doi: 10.1016/j.fertnstert.2007.12.077. Epub 2008 Jul 21. Review.</citation>
    <PMID>18639875</PMID>
  </reference>
  <reference>
    <citation>Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004379. doi: 10.1002/14651858.CD004379.pub3. Review.</citation>
    <PMID>20091563</PMID>
  </reference>
  <reference>
    <citation>Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. J Hum Reprod Sci. 2016 Apr-Jun;9(2):70-81. doi: 10.4103/0974-1208.183515. Review.</citation>
    <PMID>27382230</PMID>
  </reference>
  <reference>
    <citation>Bastu E, Buyru F, Ozsurmeli M, Demiral I, Dogan M, Yeh J. A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:30-4. doi: 10.1016/j.ejogrb.2016.05.027. Epub 2016 May 24.</citation>
    <PMID>27236602</PMID>
  </reference>
  <reference>
    <citation>Ertzeid G, Storeng R. The impact of ovarian stimulation on implantation and fetal development in mice. Hum Reprod. 2001 Feb;16(2):221-5.</citation>
    <PMID>11157810</PMID>
  </reference>
  <reference>
    <citation>Van der Auwera I, D'Hooghe T. Superovulation of female mice delays embryonic and fetal development. Hum Reprod. 2001 Jun;16(6):1237-43.</citation>
    <PMID>11387298</PMID>
  </reference>
  <reference>
    <citation>Baker VL, Brown MB, Luke B, Smith GW, Ireland JJ. Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. Fertil Steril. 2015 Nov;104(5):1145-52.e1-5. doi: 10.1016/j.fertnstert.2015.07.1151. Epub 2015 Aug 18.</citation>
    <PMID>26297646</PMID>
  </reference>
  <reference>
    <citation>Escriva AM, Diaz-Garcia C, Monterde M, Rubio JM, Pellicer A. Antral Follicle Priming Before Intracytoplasmic Sperm Injection in Previously Diagnosed Low Responders: A Randomized Controlled Trial (FOLLPRIM). J Clin Endocrinol Metab. 2015 Jul;100(7):2597-605. doi: 10.1210/jc.2015-1194. Epub 2015 May 8.</citation>
    <PMID>25955224</PMID>
  </reference>
  <reference>
    <citation>Fanchin R, Cunha-Filho JS, SchonÃ¤uer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertil Steril. 2003 Feb;79(2):316-21.</citation>
    <PMID>12568840</PMID>
  </reference>
  <reference>
    <citation>Bosdou JK, Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Zepiridis L, Tarlatzis BC. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2012 Mar-Apr;18(2):127-45. doi: 10.1093/humupd/dmr051. Epub 2012 Feb 3. Review.</citation>
    <PMID>22307331</PMID>
  </reference>
  <reference>
    <citation>Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J, Wolf JP, Hugues JN. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique--a prospective, randomized, double-blind study. Hum Reprod. 2006 May;21(5):1204-11. Epub 2006 Feb 13.</citation>
    <PMID>16476678</PMID>
  </reference>
  <reference>
    <citation>Balasch J, FÃ¡bregues F, PeÃ±arrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod. 2006 Jul;21(7):1884-93. Epub 2006 Mar 3.</citation>
    <PMID>16517559</PMID>
  </reference>
  <reference>
    <citation>FÃ¡bregues F, PeÃ±arrubia J, Creus M, Manau D, Casals G, Carmona F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod. 2009 Feb;24(2):349-59. doi: 10.1093/humrep/den428. Epub 2008 Dec 3.</citation>
    <PMID>19054777</PMID>
  </reference>
  <reference>
    <citation>Kim CH, Howles CM, Lee HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril. 2011 Feb;95(2):679-83. doi: 10.1016/j.fertnstert.2010.07.1077.</citation>
    <PMID>20801436</PMID>
  </reference>
  <reference>
    <citation>Kim CH, Ahn JW, Moon JW, Kim SH, Chae HD, Kang BM. Ovarian Features after 2 Weeks, 3 Weeks and 4 Weeks Transdermal Testosterone Gel Treatment and Their Associated Effect on IVF Outcomes in Poor Responders. Dev Reprod. 2014 Sep;18(3):145-52. doi: 10.12717/DR.2014.18.3.145.</citation>
    <PMID>25949183</PMID>
  </reference>
  <reference>
    <citation>Bosdou JK, Venetis CA, Dafopoulos K, Zepiridis L, Chatzimeletiou K, Anifandis G, Mitsoli A, Makedos A, Messinis IE, Tarlatzis BC, Kolibianakis EM. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Hum Reprod. 2016 May;31(5):977-85. doi: 10.1093/humrep/dew028. Epub 2016 Mar 7.</citation>
    <PMID>26956551</PMID>
  </reference>
  <reference>
    <citation>Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998 Jun 15;101(12):2622-9.</citation>
    <PMID>9637695</PMID>
  </reference>
  <reference>
    <citation>Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab. 1999 Aug;84(8):2951-6.</citation>
    <PMID>10443703</PMID>
  </reference>
  <reference>
    <citation>Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol. 2010 Jul;24(7):1393-403. doi: 10.1210/me.2010-0006. Epub 2010 May 25.</citation>
    <PMID>20501640</PMID>
  </reference>
  <reference>
    <citation>Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, MÃ¸llgÃ¥rd K, Wreford Andersen E, Byskov AG, Yding Andersen C. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod. 2011 Jan;17(1):63-70. doi: 10.1093/molehr/gaq073. Epub 2010 Sep 14.</citation>
    <PMID>20843821</PMID>
  </reference>
  <reference>
    <citation>Walters KA. Role of androgens in normal and pathological ovarian function. Reproduction. 2015 Apr;149(4):R193-218. doi: 10.1530/REP-14-0517. Epub 2014 Dec 16. Review.</citation>
    <PMID>25516989</PMID>
  </reference>
  <reference>
    <citation>Fooladi E, Reuter SE, Bell RJ, Robinson PJ, Davis SR. Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause. 2015 Jan;22(1):44-9. doi: 10.1097/GME.0000000000000259.</citation>
    <PMID>24845394</PMID>
  </reference>
  <reference>
    <citation>Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011 Jul;26(7):1768-74. doi: 10.1093/humrep/der106. Epub 2011 May 10.</citation>
    <PMID>21558332</PMID>
  </reference>
  <reference>
    <citation>National Collaborating Centre for Womenâs and Childrenâs Health (UK). Fertility: Assessment and Treatment for People with Fertility Problems. London: Royal College of Obstetricians &amp; Gynaecologists; 2013 Feb.</citation>
    <PMID>25340218</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Poor Ovarian Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

